Search results
Results from the WOW.Com Content Network
One study found that fluoroquinolone use was associated with a 1.9-fold increase in tendon problems. The risk increased to 3.2 in those over 60 years of age and to 6.2 in those over the age of 60 who were also taking corticosteroids. Among the 46,766 quinolone users in the study, 38 (0.08%) cases of Achilles tendon rupture were identified. [59]
Antibiotics that usually have activity against vancomycin-resistant Enterococcus (VRE): . Linezolid and Tedizolid; Streptogramins such as quinupristin-dalfopristin; Advanced generation tetracyclines: Tigecycline, Omadacycline, Eravacycline
[32] [39] [40] [41] A U.S. Centers for Disease Control and Prevention study found people treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin ...
Equianalgesic charts are used for calculation of an equivalent dose ... 30 mg IV (est.) 80–100% ... 50 μg Ocfentanil: 125–250 40–80 μg Ro4-1539: 240–480
Ciprofloxacin/celecoxib or PrimeC is a fixed-dose combination of ciprofloxacin and celecoxib developed for ALS. [1] [2] References
Tetracyclines are generally used in the treatment of infections of the urinary tract, respiratory tract, and the intestines and are also used in the treatment of chlamydia, especially in patients allergic to β-lactams and macrolides; however, their use for these indications is less popular than it once was due to widespread development of resistance in the causative organisms.
The most reported adverse effects of phase I studies included headache, rhinitis, pain, dyspepsia, and dysmenorrhea. Investigators did not believe that any of these were directly treatment-related, as many of these events are considered symptoms or manifestations of the underlying illness.
The main result was a relative risk (RR) of 0.40 (95% confidence interval (CI) 0.31 to 0.52) for development of active tuberculosis over two years or longer for patients treated with INH, with no significant difference between treatment courses of six or 12 months (RR 0.44, 95% CI 0.27 to 0.73 for six months, and 0.38, 95% CI 0.28 to 0.50 for ...